Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders

被引:69
|
作者
Li, Peng [1 ]
Zhang, Qiang [1 ]
Robichaud, Albert J. [2 ]
Lee, Taekyu [2 ]
Tomesch, John [1 ]
Yao, Wei [1 ]
Beard, J. David [1 ]
Snyder, Gretchen L. [1 ]
Zhu, Hongwen [1 ]
Peng, Youyi [1 ]
Hendrick, Joseph P. [1 ]
Vanover, Kimberly E. [1 ]
Davis, Robert E. [3 ]
Mates, Sharon [1 ]
Wennogle, Lawrence P. [1 ]
机构
[1] Intracellular Therapies Inc, New York, NY 10032 USA
[2] Bristol Myers Squibb Res & Dev, Med Chem, Princeton, NJ 08543 USA
[3] 3D Pharmaceut Consultants Inc, San Diego, CA 92130 USA
关键词
5-HT2C RECEPTORS; NEUROLEPTICS; ANTAGONISTS; AFFINITIES; RATS;
D O I
10.1021/jm401958n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D-2 receptors. This work has led to the discovery of 44(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5] pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D-2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.
引用
收藏
页码:2670 / 2682
页数:13
相关论文
共 50 条
  • [21] Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia
    Wu, Yue
    Zhang, Linjian
    Sun, Zhuoli
    Qiu, Xusheng
    Chen, Yafen
    Su, Kaijun
    Yang, Le
    Du, Zhongqiu
    Dong, Ying
    Yang, Fulai
    Li, Xiang
    Zhang, Xiaojin
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (13) : 8545 - 8563
  • [22] Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression
    Degnan, Andrew P.
    Tora, George O.
    Huang, Hong
    Conlon, David A.
    Davis, Carl D.
    Hanumegowda, Umesh M.
    Hou, Xiaoping
    Hsiao, Yi
    Hu, Joanna
    Krause, Rudolph
    Li, Yu-Wen
    Newton, Amy E.
    Pieschl, Rick L.
    Raybon, Joseph
    Rosner, Thorsten
    Sun, Jung-Hui
    Taber, Matthew T.
    Taylor, Sarah J.
    Wong, Michael K.
    Zhang, Huiping
    Lodge, Nicholas J.
    Bronson, Joanne J.
    Macor, John E.
    Gillman, Kevin W.
    ACS CHEMICAL NEUROSCIENCE, 2016, 7 (12): : 1635 - 1640
  • [23] Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies
    Bezencon, Olivier
    Heidmann, Bibia
    Siegrist, Romain
    Stamm, Simon
    Richard, Sylvia
    Pozzi, Davide
    Corminboeuf, Olivier
    Roch, Catherine
    Kessler, Melanie
    Ertel, Eric A.
    Reymond, Isabelle
    Pfeifer, Thomas
    de Kanter, Ruben
    Toeroek-Schafroth, Michael
    Moccia, Luca G.
    Mawet, Jacques
    Moon, Richard
    Rey, Markus
    Capeleto, Bruno
    Fournier, Elvire
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (23) : 9769 - 9789
  • [24] Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate
    Song, Yu'ning
    Lin, Xiaoqian
    Kang, Dongwei
    Li, Xiao
    Zhan, Peng
    Liu, Xinyong
    Zhang, Qingzhu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 82 : 293 - 307
  • [25] Discovery and Characterization of 4-Hydroxy-2-pyridone Derivative Sambutoxin as a Potent and Promising Anticancer Drug Candidate: Activity and Molecular Mechanism
    Li, Lu-Ning
    Wang, Lei
    Cheng, Yan-Na
    Cao, Zhan-Qi
    Zhang, Xin-Ke
    Guo, Xiu-Li
    MOLECULAR PHARMACEUTICS, 2018, 15 (11) : 4898 - 4911
  • [26] Discovery and Development of Orally Active Antivirals for the Treatment of RSV: Identification of BTA9881 and a 2nd Generation Candidate
    Tucker, Simon
    Draffan, Alistair
    Fenner, Jennifer
    Iswaran, Jega
    Luttick, Angela
    McCarthy, Mike
    Pitt, Gary
    Ryan, Jane
    ANTIVIRAL RESEARCH, 2011, 90 (02) : A46 - A47
  • [27] Importance of developability criteria in the discovery of clinical candidate SB-435495:: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2.
    Smith, SA
    Blackie, JA
    Bloomer, JC
    Brown, MJB
    Cheng, HY
    Elliott, RL
    Hammond, B
    Hickey, DMB
    Ife, RJ
    Leach, CA
    Lewis, VA
    Macphee, CH
    Milliner, KJ
    Moores, KE
    Pinto, IL
    Stansfield, IG
    Stanway, SJ
    Taylor, MA
    Theobald, CJ
    Whittaker, CM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U62 - U62
  • [28] Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
    Xiang, Weiguo
    Zhao, Lijie
    Han, Xin
    Qin, Chong
    Miao, Bukeyan
    McEachern, Donna
    Wang, Yu
    Metwally, Hoda
    Kirchhoff, Paul D.
    Wang, Lu
    Matvekas, Aleksas
    He, Miao
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13487 - 13509
  • [29] Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer
    Yao, Wenqing
    Zhuo, Jincong
    Burns, David M.
    Xu, Meizhong
    Zhang, Colin
    Li, Yun-Long
    Qian, Ding-Quan
    He, Chunhong
    Weng, Lingkai
    Shi, Eric
    Lin, Qiyan
    Agrios, Costas
    Burn, Timothy C.
    Caulder, Eian
    Covington, Maryanne B.
    Fridman, Jordan S.
    Friedman, Steven
    Katiyar, Kamna
    Hollis, Gregory
    Li, Yanlong
    Liu, Changnian
    Liu, Xiangdong
    Marando, Cindy A.
    Newton, Robert
    Pan, Max
    Scherle, Peggy
    Taylor, Nancy
    Vaddi, Kris
    Wasserman, Zelda R.
    Wynn, Richard
    Yeleswaram, Swamy
    Jalluri, Ravi
    Bower, Michael
    Zhou, Bing-Bing
    Metcalf, Brian
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) : 603 - 606
  • [30] Discovery of TAK-441, a pyrrolo[3, 2-c]pyridine derivative: A highly potent and orally active investigational hedgehog signaling inhibitor
    Sasaki, Satoshi
    Ohashi, Tomohiro
    Oguro, Yuya
    Tanaka, Toshio
    Shiokawa, Zenyu
    Fujii, Nobuhiro
    Shibata, Sachio
    Sato, Yoshihiko
    Sagiya, Yoji
    Yamakawa, Hiroko
    Hattori, Harumi
    Miyamoto, Maki
    Kondo, Shigeru
    Ishimura, Yoshimasa
    Tojo, Hideaki
    Baba, Atsuo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242